Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa

Vaccine

Volumn 18, Issue 21, 2000, Pages 2266-2274

  Staczek, John ^a   Bendahmane, Mohammed ^b   Gilleland, Linda B ^a   Beachy, Roger N ^b   Gilleland Jr, Harry E ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Donald Danforth Plant Sci C ^*  (United States)

Author keywords

Bacterial vaccine; Chimeric virus; OM protein F; Pseudomonas aeruginosa; Tobacco mosaic virus

Indexed keywords

BACTERIAL VACCINE; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONTROLLED STUDY; DRUG EFFECT; EPITOPE MAPPING; IMMUNIZATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTECTION; PSEUDOMONAS AERUGINOSA; TOBACCO MOSAIC VIRUS; VACCINATION;

ANIMALS; BACTERIAL VACCINES; CHIMERA; FEMALE; IMMUNIZATION; MICE; MICE, INBRED ICR; PORINS; PSEUDOMONAS AERUGINOSA; TOBACCO MOSAIC VIRUS; VACCINES, SYNTHETIC;

EID: 0034009355     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00571-X     Document Type: Article

References (33)

1. Woods D.E., Bryan L.E. Studies on the ability of alginate to act as a protective immunogen against infection with Pseudomonas aeruginosa in animals. J. Infect. Dis. 151:1985;581-587.
2. Pier G.B., Small G.J., Warren H.B. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science. 249:1990;537-549.
3. Langford D.T., Hiller J. Prospective, controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis - three year results. Arch. Dis. Child. 59:1984;1131-1134.
4. Jones R.J., Roe E.A., Gupta J.L. Controlled trials of a polyvalent Pseudomonas vaccine in burns. Lancet. 2:1979;977-982.
5. Campbell A.P., Wong W.Y., Houston M. Jr, Schweizer F., Cachia P.J., Irvin R.T., Hindsgaul O., Hodges R.S., Sykes B.D. Interaction of the receptor binding domains of Pseudomonas aeruginosa pili strains PAK, PAO, KB7 and P1 to a cross-reactive antibody and receptor analog: implications for synthetic vaccine design. J. Molec. Biol. 267:1997;382-402.
6. Hahn H., Lane-Bell P.M., Glasier L.M., Nomellini J.F., Bingle W.H., Paranchych W., Smit J. Pilin-based anti-Pseudomonas vaccines: latest developments and perspectives. Behring Inst. Mitt. 98:1997;315-325.
7. Doring G., Pfeiffer C., Weber U., Mohr-Pennert A., Dorner F. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals. American Journal of Respiratory & Critical Care Medicine. 151:1995;983-985.
8. Doring G., Dorner F. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Inst. Mitt. 98:1997;338-344.
9. Matthews-Greer J.M., Robertson D.E., Gilleland L.B., Gilleland H.E. Jr. Pseudomonas aeruginosa outer membrane protein F produced in Escherichia coli retains vaccine efficacy. Curr. Microbiol. 20:1990;171-175.
10. Fox C.W., Campbell G.D. Jr, Anderson M.M., Zavecz J.H., Gilleland L.B., Gilleland H.E. Jr. Preservation of pulmonary function by an outer membrane protein F vaccine: a study in rats with chronic pulmonary infection caused by Pseudomonas aeruginosa. Chest. 105:1984;1545-1550.
11. Matthews-Greer J.M., Gilleland H.E. Jr. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J. Infect. Dis. 155:1987;1282-1291.
12. von Specht B.-U., Knapp B., Muth G., Broker M., Hungerer K., Diehl K., Massarrat K., Seemann A., Domdey H. Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect. Immun. 63:1995;1855-1862.
13. von Specht B.-U., Knapp B., Hungerer K.-D., Lucking C., Schmitt A., Domdey H. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates. J. Biotech. 44:1996;145-153.
14. von Specht B.U., Lucking H.C., Blum B., Schmitt A., Hungerer K.D., Domdey H. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers. Vaccine. 14:1996;1111-1117.
15. Mansouri E., Gabelsberger J., Knapp B., Hundt E., Lenz U., Hungerer K.D., Gilleland H.E. Jr, Staczek J., Domdey H., von Specht B.U. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect. Immun. 67:1999;1461-1470.
16. Gilleland H.E. Jr, Parker M.G., Matthews J.M., Berg R.D. Use of purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect. Immun. 44:1984;49-54.
17. Gilleland H.E. Jr, Gilleland L.B., Matthews-Greer J.M. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect. Immun. 56:1988;1017-1022.
18. Hughes E.E., Gilleland L.B., Gilleland H.E. Jr. Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa. Infect. Immun. 60:1992;3497-3503.
19. Gilleland H.E. Jr, Hughes E.E., Gilleland L.B., Matthews-Greer J.M., Staczek J. Use of synthetic peptides to identify surface-exposed, B cell epitopes within outer membrane protein F of Pseudomonas aeruginosa. Curr. Microbiol. 31:1995;279-286.
20. Hughes E.E., Gilleland H.E. Jr. Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine model. Vaccine. 13:1995;1750-1753.
21. Gilleland L.B., Gilleland H.E. Jr. Synthetic peptides representing two protective, linear B-cell epitopes of outer membrane protein F of Pseudomonas aeruginosa elicit whole-cell-reactive antibodies that are functionally pseudomonad specific. Infect. Immun. 63:1995;2347-2351.
22. Staczek J., Gilleland H.E. Jr, Gilleland L.B., Harty R.N., Garcia-Sastre A., Engelhardt O.G., Palese P. A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection. Infect. Immun. 66:1998;3990-3994.
23. Brennan F.R., Gilleland L.B., Staczek J., Bendig M.M., Hamilton W.D.O., Gilleland H.E. Jr. A chimaeric virus vaccine protects mice against a bacterial infection. Microbiology. 145:1999;2061-2067.
24. Bendahmane M., Koo M., Karrer E., Beachy R.N. Display of epitopes on the surface of tobacco mosaic virus: Impact of charge and isoelectric point of the epitope on virus-host interactions. J. Molec. Biol. 290:1999;9-20.
25. Koo M., Bendahmane M., Latterri G., Paoletti E., Fitchen J., Buchmeier M., Beachy R.N. Protective immunity against murine hepatitis virus induced by intranasal and subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proceedings of the National Academy of Sciences, USA. 96:1999;7774-7779.
26. Bendahmane M., Fitchen J.H., Zhang G., Beachy R.N. Studies of coat protein-mediated resistance to tobacco mosaic tobamovirus: correlation between assembly of mutant coat proteins and resistance. J. Virol. 71:1997;7942-7950.
27. Asselin A., Zaitlin M. Characterization of a second protein associated with virions of tobacco mosaic virus. Virology. 91:1978;173-181.
28. Gilleland H.E. Jr, Gilleland L.B., Hughes E.E., Matthews-Greer J.M. Recombinant outer membrane protein F of Pseudomonas aeruginosa elicits antibodies that mediate opsonophagocytic killing, but not complement-mediated bacteriolysis, of various strains of P. aeruginosa. Curr. Microbiol. 24:1992;1-7.
29. Starke J.R., Edwards M.S., Langston C., Baker C.J. A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr. Res. 22:1987;698-702.
30. Brennan F.R., Jones T.D., Gilleland L.B., Bellaby T., Xu F., North P.C., Thomson A., Staczek J., Lin T., Johnson J.E., Hamilton W.D.O., Gilleland H.E. Jr. Pseudomonas aeruginosa outer membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. Microbiology. 145:1999;211-220.
31. Beachy R.N., Fitchen J.H., Hein M.B. Use of plant viruses for delivery of vaccine epitopes. Ann. N. Y. Acad. Sci. 792:1996;43-49.
32. Fitchen J., Beachy R.N., Hein M.B. Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Vaccine. 13:1995;1051-1057.
33. Holt C.A., Beachy R.N. In vivo complementation of infectious transcripts from mutant tobacco mosaic virus cDNAs in transgenic plants. Virology. 181:1991;109-117.